# Treace Medical Concepts share price today (Treace Medical Concepts, Inc., TMCI)

> Treace Medical Concepts, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. TMCI · Healthcare · Medical Devices · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/tmci

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $4.28 (−33.0% in a year)
- Revenue (Jun 2026): $45.4 M (−4.2% on a year ago)
- Profit (Jun 2026): −$15.9 M
- Operating margin: −33.0% (+2.8 points on a year ago)
- ROE: −68%, FY25
- ROIC: −21.8%, against a 11.5% cost of capital: −33.3 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Treace Medical Concepts share price today? Treace Medical Concepts, Inc.'s share price was $4.28 at the close on 3 November 2026. That is 31.7% above its average price over the last 200 trading days. In the last 52 weeks it traded between $1 and $5, and at that close it sat 85% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 1 week running. Over the last 1 year the share price moved −29% while the S&P 500 moved +21%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Treace Medical Concepts pay? Treace Medical Concepts, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Treace Medical Concepts on? Treace Medical Concepts is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Treace Medical Concepts profitable? Treace Medical Concepts, Inc. posted a net loss of $15.9 M in the Jun 2026 quarter. The full FY25 year was a loss of $59.0 M. That loss is 35.0% of the quarter's revenue. The same quarter a year earlier lost $17.4 M. 12 of the last 12 reported quarters were loss-making. ## How much revenue does Treace Medical Concepts make, and is it growing? Treace Medical Concepts, Inc. reported $45.4 M of revenue in the Jun 2026 quarter, −4.2% on the same quarter a year earlier. Over 4 years it has grown 22.5% a year on average. The last full year, FY25, came in at $213 M. The last four reported quarters add to $205 M. FY25 revenue was $213 M, +1.6% on the year before. Recent pace: the last four quarters grew −3.0% on average, against 22.5% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −4.0%, against +1.7% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does Treace Medical Concepts keep? Treace Medical Concepts, Inc.'s operating margin was −33.0% in the Jun 2026 quarter, 2.8 percentage points higher than the same quarter a year ago. Across 5 years it has been between −27.5% and −17.5%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed +2.8 percentage points on the year while gross margin changed −1.2 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Treace Medical Concepts' profit turning into cash? Treace Medical Concepts, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $16.0 M of cash, against −$59.0 M of profit. After $13.5 M of spending on assets, free cash was −$29.5 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Treace Medical Concepts' cash go? Treace Medical Concepts, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $36.6 M on assets over the last 3 years. Averaged over those years that is 5.7% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $36.6 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Treace Medical Concepts' P/E ratio, and how does it compare with its own history? Treace Medical Concepts, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Treace Medical Concepts, Inc. at 1.3× its FY25 revenue of $213 M. The P/E comes back here once profit turns positive. ## Is the Treace Medical Concepts business getting better or worse? Treace Medical Concepts, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Treace Medical Concepts earn on its capital? Treace Medical Concepts, Inc. earned a ROE of −68% in FY25. That is up from a low of −71% in FY22. Its return on capital used (ROIC) is 33.3 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −27.7% net margin and 1.12× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −27.7% net margin × 1.12× asset turnover × 2.18× leverage (assets divided by equity) ≈ −67.6% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: −21.8% − 11.5% = −33.3 percentage points. The 11.5% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Treace Medical Concepts have too much debt? Treace Medical Concepts, Inc. has total debt of $73.0 M against shareholder equity of $67.7 M as of Jun 2026, so its debt is 1.08× its equity. Year by year, that ratio went from 0.32 in FY21 to 0.82 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Treace Medical Concepts shareholding pattern? 4.0% of Treace Medical Concepts, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 8.4 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Treace Medical Concepts from balance-sheet trouble? For Treace Medical Concepts, Inc., the Z-score is −0.18. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −0.18 is inside the danger zone, so the balance sheet is a real risk. ## How does Treace Medical Concepts rank in its industry? There is no score against its industry: Treace Medical Concepts, Inc. is not among the largest members shown in this industry comparison for Medical Devices. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Treace Medical Concepts compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Treace Medical Concepts in size? Treace Medical Concepts is the 67th largest of 75 Medical Devices companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Mobia Medical, Inc., ClearPoint Neuro, Inc. and Quantum-Si incorporated. Just below it: Profound Medical Corp., InfuSystem Holdings, Inc. and Standard BioTools Inc. ### Medical Devices companies close in size

1. [Mobia Medical, Inc.](https://www.sectoralpha.in/us/stocks/mobi) $332 million
2. [ClearPoint Neuro, Inc.](https://www.sectoralpha.in/us/stocks/clpt) $311 million
3. [Quantum-Si incorporated](https://www.sectoralpha.in/us/stocks/qsi) $285 million
4. Treace Medical Concepts, Inc. $278 million
5. [Profound Medical Corp.](https://www.sectoralpha.in/us/stocks/prof) $255 million
6. [InfuSystem Holdings, Inc.](https://www.sectoralpha.in/us/stocks/infu) $255 million
7. [Standard BioTools Inc.](https://www.sectoralpha.in/us/stocks/lab) $240 million

[All 75 Medical Devices companies, largest first](https://www.sectoralpha.in/us/sectors/medical-devices#all-companies)

### Companies close in size in other industries

1. [Seaport Entertainment Group Inc.](https://www.sectoralpha.in/us/stocks/seg) $289 million · Real Estate Services
2. [Bit Digital, Inc.](https://www.sectoralpha.in/us/stocks/btbt) $288 million · Capital Markets
3. Treace Medical Concepts, Inc. $288 million
4. [CN Healthy Food Tech Group Corp.](https://www.sectoralpha.in/us/stocks/ucfi) $288 million · Packaged Foods
5. [M-tron Industries, Inc.](https://www.sectoralpha.in/us/stocks/mpti) $288 million · Electronic Components

## What else do people ask about Treace Medical Concepts? ### What were Treace Medical Concepts's latest quarterly results? Treace Medical Concepts, Inc. reported revenue of $45.4 M and a net loss of $15.9 M for the Jun 2026 quarter. Earnings per share were −$0.24. The operating margin was −33.0%, 2.8 percentage points higher than a year earlier (as of 3 November 2026). ### What is Treace Medical Concepts's market cap? Treace Medical Concepts, Inc.'s market capitalisation is $278 M at a stock price of $4.28. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Treace Medical Concepts performing? Treace Medical Concepts, Inc.'s latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 1 week running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Treace Medical Concepts's stock price go up? This page does not forecast Treace Medical Concepts, Inc.'s stock price. What it shows instead: the stock price is $4.28. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Treace Medical Concepts in its business cycle? Treace Medical Concepts, Inc.'s FY25 operating margin was −25.5%, against a 5-year range of −27.5% to −17.5%: the low end of its own range, which is often where recoveries start. The latest quarter was −33.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Treace Medical Concepts story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Treace Medical Concepts a stock worth studying right now? What the numbers show: Treace Medical Concepts, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.